nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.10.2009 | Original Paper

Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP

verfasst von: Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Toshiki Yamada, Michio Sawada, Hideko Goto, Kenji Fukuno, Jun-ichi Kitagawa, Ichiro Yasuda, Naoki Katsumura, Masao Takemura, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

We previously reported that serum concentrations of soluble Fas (sFas) predict the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) after treatment with CHOP but without rituximab (R). Here, we investigated whether the role of sFas as a prognostic factor remains valid in the R-CHOP era.

Patients

We treated 132 patients with DLBCL between October 1995 and September 2002 (group A: without rituximab), and 75 between December 2002 and March 2007 (group B: with rituximab). The patients received eight cycles of CHOP or THP (tetrahydropyranyl-adriamycin)-COP before September 2002, and R-CHOP or R-THP-COP after October 2002. The distribution of patients according to the International Prognostic Index did not significantly differ between the groups.

Results

The 5-year overall survival (OS) rates for patients with sFas levels of ≥3.0 and <3.0 ng/ml in group A were 19.8 and 61.9% (P < 0.0001), whereas the 3-year OS rates in group B were 54.7 and 92.2% (P < 0.01), respectively. Multivariate analysis using the proportional hazards model revealed that sFas most significantly correlated with overall survival (P < 0.05).

Conclusion

Serum sFas is thus a useful tool for selecting the appropriate therapeutic strategy for DLBCL.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511. doi:10.1038/35000501 CrossRefPubMed

Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759–1762. doi:10.1126/science.7510905 CrossRefPubMed

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253PubMed

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242. doi:10.1056/NEJMoa011795 CrossRefPubMed

Fisher RI, Shah P (2003) Current trends in large cell lymphoma. Leukemia 17:1948–1960. doi:10.1038/sj.leu.2403096 CrossRefPubMed

Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas Ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189–1192. doi:10.1126/science.270.5239.1189 CrossRefPubMed

Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Brière J, Gaulard P, Reyes F (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87-2. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 15:1131–1137PubMed

Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M, Takahashi T, Moriwaki H (2000) Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin’s lymphoma. Am J Hematol 64:257–261. doi:10.1002/1096-8652(200008)64:4<257::AID-AJH4>3.0.CO;2-2 CrossRefPubMed

Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534. doi:10.1056/NEJM199708213370804 CrossRefPubMed

Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors, pathology and genetics tumors of haematopoietic and lymphoid tissues. IARC, Lyon, pp 109–236

Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S (2003) Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: an Italian multicenter randomized trial. J Clin Oncol 21:1255–1262. doi:10.1200/JCO.2003.01.117 CrossRefPubMed

Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261–268. doi:10.1002/mpo.2950220410 CrossRefPubMed

Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287–1295. doi:10.1056/NEJMoa031770 CrossRefPubMed

Nagata S (1997) Apoptosis by death factor. Cell 88:355–365. doi:10.1016/S0092-8674(00)81874-7 CrossRefPubMed

Nicolaides C, Dimou S, Pavlidisa N (1998) Prognostic factors in aggressive non-Hodgkin’s lymphomas. Oncologist 3:189–197PubMed

Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y (1999) Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin’s lymphoma. Blood 94:3541–3550PubMed

Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S, Hirano M, Honma Y (2001) Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97:1202–1210. doi:10.1182/blood.V97.5.1202 CrossRefPubMed

Niitsu N, Honma Y, Iijima K, Takagi T, Higashihara M, Sawada U, Okabe-Kado J (2003) Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin’s lymphoma. Leukemia 17:196–202. doi:10.1038/sj.leu.2402699 CrossRefPubMed

Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G (1996) An N-terminal domain shared by Fas/Apo-1(CD95) soluble variants prevents cell death in vitro. J Immunol 156:4622–4630PubMed

Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354–361. doi:10.1034/j.1600-0609.2002.01654.x CrossRefPubMed

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861. doi:10.1182/blood-2006-08-038257 CrossRefPubMed

Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol 17:423–429PubMed

Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 75:1169–1178. doi:10.1016/0092-8674(93)90326-L CrossRefPubMed

Takagi T, Oguro M (1987) (2″-R)-4′-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151–154. doi:10.1007/BF00253970 CrossRefPubMed

The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994. doi:10.1056/NEJM199309303291402 CrossRef

The Non-Hodgkin’s Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 49:2112–2135. doi:10.1002/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2 CrossRef

Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107–113. doi:10.1007/s00432-003-0508-9 CrossRefPubMed

Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M, Takami T, Moriwaki H (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 25:107–114. doi:10.1002/hon.815 CrossRefPubMed

Titel: Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP
verfasst von: Takeshi Hara
Hisashi Tsurumi
Naoe Goto
Nobuhiro Kanemura
Takeshi Yoshikawa
Senji Kasahara
Toshiki Yamada
Michio Sawada
Hideko Goto
Kenji Fukuno
Jun-ichi Kitagawa
Ichiro Yasuda
Naoki Katsumura
Masao Takemura
Takeshi Takahashi
Tsuyoshi Takami
Hisataka Moriwaki
Publikationsdatum: 01.10.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0586-4

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP

Abstract

Introduction

Patients

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Introduction

Patients

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2009

A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment

A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma

Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China

APC mutation spectrum of Norwegian familial adenomatous polyposis families: high ratio of novel mutations

Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo

The antiangiogenic effects of tyroservatide on animal models of hepatocellular carcinoma

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie